文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

MPT64分泌作为活力相关免疫检测读数用于结核分枝杆菌快速表型药敏分类的概念验证研究

MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis: a proof-of-concept study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究评估了MPT64分泌作为活力相关读数用于结核分枝杆菌快速表型药敏试验(pDST)的性能,在130株结核分枝杆菌中检测对利福平、异烟肼和莫西沙星的敏感性。结果显示MPT64-pDST与参考药敏试验分类一致性高,对利福平、异烟肼和莫西沙星耐药检测灵敏度分别为100%、98%和90%,无假耐药分类。研究提示该免疫检测法可实现快速表型药敏分类,但需更大样本验证。

要点

  • MPT64-pDST对利福平、异烟肼和莫西沙星耐药检测灵敏度分别为100%、98%和90%。
  • 利福平、异烟肼和莫西沙星均无假耐药分类,与参考药敏试验分类一致性高。
  • 探索性分析显示MPT64-pDST可区分利奈唑胺敏感与耐药突变株。

核心结论

  • MPT64-pDST概念验证可实现利福平、异烟肼和莫西沙星的快速表型药敏分类。

研究设计与样本

  • 评估130株结核分枝杆菌,包括临床分离株、WHO质量评估株和体外筛选耐药突变株(仅利奈唑胺)。
  • MPT64通过化学发光酶免疫法量化,根据相对于无药对照的Log2倍数变化推断敏感性。
  • 参考标准:利福平、异烟肼、利奈唑胺和贝达喹啉采用最低抑菌浓度检测,莫西沙星采用基于MGIT的药敏试验。
  • 采用受试者工作特征曲线分析、全数据集Youden最优候选截断值和2000次分层bootstrap袋外内部验证评估性能。

主要发现

  • 使用药物特异性全数据集Youden最优候选截断值,MPT64-pDST与参考药敏试验分类一致性高,利福平、异烟肼和莫西沙星均无假耐药分类。
  • 耐药检测灵敏度:利福平100%、异烟肼98%、莫西沙星90%,袋外bootstrap估计与全数据集估计相当。
  • 利奈唑胺探索性分析显示敏感与耐药突变株可分离。
  • 单一贝达喹啉耐药分离株与39株贝达喹啉敏感分离株清晰可区分。

关键数值与推荐

  • 利福平耐药检测灵敏度100%,异烟肼98%,莫西沙星90%,均基于药物特异性全数据集Youden最优候选截断值。
  • 利福平、异烟肼和莫西沙星均无假耐药分类。
  • 莫西沙星参考标准为基于MGIT的药敏试验,其余药物为最低抑菌浓度检测。

临床怎么用

  • MPT64-pDST作为活力相关免疫检测读数,有望用于结核分枝杆菌对利福平、异烟肼和莫西沙星的快速表型药敏分类。
  • 需在更大分离株集合中进一步验证,包括临界表型分离株。

局限性

  • 需在更大分离株集合中进一步验证,包括临界表型分离株。
  • 利奈唑胺和贝达喹啉仅为探索性分析,利奈唑胺耐药突变株为体外筛选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate MPT64 secretion as a viability-associated readout for rapid phenotypic drug susceptibility testing (pDST) of Mycobacterium tuberculosis. METHODS: We evaluated MPT64-pDST in 130 M. tuberculosis strains: clinical isolates, WHO quality assessment strains and in vitro-selected resistant mutants (for linezolid only). We assessed the diagnostic performance of MPT64-pDST for determining susceptibility to rifampicin, isoniazid and moxifloxacin. As a secondary objective, we explored its performance for linezolid and bedaquiline. MPT64 was quantified by chemiluminescent enzyme immunoassay, and susceptibility was inferred from Log2 fold change relative to drug-free controls. Reference standards were minimum inhibitory concentration testing for rifampicin, isoniazid, linezolid and bedaquiline and MGIT-based DST for moxifloxacin. Performance was evaluated using receiver operating characteristic analysis, full-dataset Youden-optimal candidate cutoffs and 2000-iteration stratified bootstrap out-of-bag (OOB) internal validation. RESULTS: Using drug-specific full-dataset Youden-optimal candidate cutoffs, MPT64-pDST showed high categorical agreement with reference DST, with no false-resistant classifications for rifampicin, isoniazid or moxifloxacin. Resistance-detection sensitivity was 100% for rifampicin, 98% for isoniazid and 90% for moxifloxacin, and out-of-bag bootstrap estimates were comparable to the full-dataset estimates. Exploratory analyses for linezolid demonstrated separation between susceptible and resistant mutants. The single bedaquiline-resistant isolate was clearly distinguishable from 39 bedaquiline-susceptible isolates. CONCLUSIONS: These findings provide proof of concept that the immunoassay-based MPT64-pDST can enable rapid phenotypic susceptibility classification for rifampicin, isoniazid and moxifloxacin. Further validation in larger isolate collections, including isolates with borderline phenotypes, is warranted.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Murase, Takeuchi, Ohtaki, et al. MPT64 secretion as a viability-associated immunoassay readout for rapid phenotypic drug susceptibility classification of Mycobacterium tuberculosis: a proof-of-concept study. J Antimicrob Chemother. 2026. PMID: 42948968. doi:10.1093/jac/dkag358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。